Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD

• Main Authors: Maneeton,N., Maneeton,B., Suttajit,S., Reungyos,J., Srisurapanont,M., Martin,S.D.
• 格式: Article
• 出版: Dove Medical Press Ltd. 2015
• 主題: Drug Discovery; Pharmaceutical Science; Pharmacology
• 在線閱讀: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84908066180&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38319
• 機構: Chiang Mai University

© 2014 Maneeton et al. Results: A total of 806 final study or safety participants were included. The dosage of lisdexamfetamine was 30 to 70 mg/day. The pooled mean scores of mean change and mean end point scores between LDX- and placebo-treated groups also had a significant difference (SMD [95% CI]...